AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 283 min read$CADL

Show Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing Nears

Candel Therapeutics (CADL) stock surged over 190% in six months due to clinical progress. CAN-2409 showed 50% 24-month survival in NSCLC and 39% improvement in prostate cancer survival. CAN-3110 is in Phase 1b for glioblastoma. CADL partnered with EVERSANA and plans a BLA filing for CAN-2409 in Q4 2026.

Original reporting
rttnews.com
Published Aug 28, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CADL
Bullish
high confidence
Mentioned
$CADL
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CADLBullishHigh
01

Why it matters

The disclosed data represent the first public release of pivotal trial outcomes, offering a fresh catalyst for the stock.

02

Market read

New trial data and regulatory filing plans provide a timely trade opportunity in the biotech space.

03

What to watch

Potential competition from other viral‑vector therapies and regulatory scrutiny could temper the rally.

Relevance 9/10Novelty 9/10Timing: today

Background

Candel Therapeutics highlighted recent clinical milestones and a pending Biologics License Application after strong Phase 3 results.

Company-level read

Ticker impact

$CADLBullishHigh confidence
Context

CADL disclosed Phase 3 trial results with a 39% improvement in disease-free survival and announced a forthcoming BLA submission for its lead cancer therapy.

Expected impact

Expect upside of 15‑25% over the next 4‑6 weeks if data is validated by the market.

Evidence & confidence

Biotech stocks typically rally on strong pivotal trial outcomes and clear regulatory pathways; the 39% DFS gain is material.

Market effects

Sector

Strengthens the oncology immunotherapy sector, potentially boosting peers with similar platforms.

Regional

Positive for U.S. biotech market, may lift related exchange-traded funds.

Global

Adds confidence to global investors tracking cancer therapy pipelines.

Counterpoint

What could challenge this read

The trial size is modest and long-term survival data remain pending; a cautious stance may be warranted.

Key entities

  • company
    Candel Therapeutics Inc.

    Biotech developing viral‑vector cancer immunotherapies.

Read at source← All news

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min